Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.31 |
| ▸ | DRD4 | P21917 | 4/20 | 0.31 |
| ▸ | DRD3 | P35462 | 4/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415721 | 0.82 | NPC1 (0.34) | — | |
| SCHEMBL1137192 | 0.72 | DRD2 (0.39) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL17459916 | 0.69 | TRPA1 (0.34) | — | |
| SCHEMBL25418098 | 0.66 | P2RX7 (0.43) | — | |
| SCHEMBL18059664 | 0.66 | P2RX7 (0.43) | — | |
| SCHEMBL25259580 | 0.66 | P2RX7 (0.43) | — | |
| SCHEMBL16338349 | 0.66 | P2RX7 (0.39) | — | |
| SCHEMBL13836558 | 0.63 | NFKB1 (0.44) | — | |
| SCHEMBL18550841 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL17459947 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200101068-A1 | Heteroaryl Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2020-04-02 | — | — | US | disclosed |
| EP-3337802-A1 | HETEROARYL DERIVATIVES AS PARP INHIBITORS | Lupin Limited (IN) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017029601-A1 | HETEROARYL DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2017-02-23 | — | — | WO | disclosed |
| WO-2016012956-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200101068-A1 | Heteroaryl Derivatives as PARP Inhibitors | PARP1, PARP2, PARP3 | DRD2 2007/4885DRD4 3481/4885DRD3 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.